ClinConnect ClinConnect Logo
Search / Trial NCT00348049

Efficacy of LASIK Versus PRK in Asians With Mild and Moderate Myopia

Launched by SINGAPORE NATIONAL EYE CENTRE · Jul 3, 2006

Trial Information

Current as of June 06, 2025

Completed

Keywords

Lasik Prk Myopia

ClinConnect Summary

This study is a prospective, randomized, clinical trial comparing the efficacy, predictability, stability and safety of LASIK versus PRK in a volunteer group of myopic military servicemen recruited from the Singapore Armed Forces. 132 subjects who were eligible for the study were randomized to undergo either LASIK or PRK in both eyes in a 2:1 ratio. 45 subjects (90 eyes) underwent PRK and 87 subjects (174 eyes) underwent LASIK.

An additional 59 subject underwent a non-randomised arm of the study and underwent PRK.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male and female subjects were eligible for the study if they were 18 years old or older and had given informed consent; had stable myopia ranging from -2.00 to -5.00D of spherical equivalent myopia, but less than 2.00D of refractive astigmatism as determined by manifest refraction for at least 6 months; a best corrected visual acuity of at least 20/20 and a stable keratometry after not wearing soft contact lenses for at least 2 weeks and hard lenses for at least 3 weeks. Study subjects were required to have a minimum cornea thickness of at least 460um as measured by Orbscan pachymetry.
  • Exclusion Criteria:
  • Subjects were excluded if they had corneal or anterior segment pathology, or myopic peripheral retinal degeneration or myopic macular degeneration; clinical signs of progressive or unstable myopia or keratoconus or were keratoconus suspects; were one-eyed patients; had undergone previous ocular surgery; had a history of herpes zoster ophthalmicus or herpes simplex keratitis; had a history of steroid-responsive rise in intraocular pressure or had a preoperative intraocular pressure of more than 21 mmHg in either eye; had diabetes mellitus, auto-immune disease, severe dry eye, connective tissue disease or significant atopy; on chronic systemic corticosteroid or immunosuppressive therapy; had a cornea thickness which would have resulted in less than 250 microns of remaining posterior corneal thickness below the flap postoperatively or had a central corneal endothelial cell count of less than 1500 cells/mm2 in either eye

About Singapore National Eye Centre

The Singapore National Eye Centre (SNEC) is a premier institution dedicated to advancing ophthalmic care through innovative research and clinical excellence. As a leading clinical trial sponsor, SNEC focuses on improving the diagnosis and treatment of a wide range of eye conditions, leveraging cutting-edge technologies and methodologies. Committed to enhancing patient outcomes, SNEC collaborates with a network of healthcare professionals and researchers to conduct rigorous clinical trials that contribute to the global understanding of ocular health. Their comprehensive approach integrates patient care with scientific inquiry, ensuring that advancements in eye care are both evidence-based and aligned with the needs of the community.

Locations

Singapore, , Singapore

Patients applied

0 patients applied

Trial Officials

Donald Tan, FAMS

Principal Investigator

Singapore Eye Research Institute

Benjamin Seet

Principal Investigator

Singapore Armed Forces

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials